{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:10:44Z","timestamp":1791907844477,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd002991.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000}}],"reference-count":251,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002991.pub4","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T10:23:31Z","timestamp":1679912611000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhaled corticosteroids versus placebo\u00a0 for stable chronic obstructive pulmonary disease"],"prefix":"10.1002","volume":"2023","author":[{"given":"Ian A","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine; The Prince Charles Hospital, Metro North Hospital and Health Service; Brisbane Australia"},{"name":"UQ Thoracic Research Centre, Faculty of Medicine; The University of Queensland; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia R","family":"Ferry","sequence":"additional","affiliation":[{"name":"UQ Thoracic Research Centre, Faculty of Medicine; The University of Queensland; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S","family":"Clarke","sequence":"additional","affiliation":[{"name":"Redcliffe Hospital; Redcliffe Australia"},{"name":"North Lakes Health Precinct; North Lakes Australia"},{"name":"Caboolture Community and Oral Health; Caboolture Australia"},{"name":"Faculty of Medicine; The University of Queensland; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther HA","family":"Sim","sequence":"additional","affiliation":[{"name":"GenesisCare Radiation Oncology; Urraween Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwun M","family":"Fong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medicine; The Prince Charles Hospital, Metro North Hospital and Health Service; Brisbane Australia"},{"name":"UQ Thoracic Research Centre, Faculty of Medicine; The University of Queensland; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/thx.53.6.477","article-title":"Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease","volume":"53","author":"Bourbeau","year":"1998","journal-title":"Thorax"},{"issue":"11","key":"10.1002\/14651858.CD002991.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/thx.2006.071068","article-title":"Effect of salmeterol\/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial","volume":"62","author":"Bourbeau","year":"2007","journal-title":"Thorax"},{"issue":"10","key":"10.1002\/14651858.CD002991.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.rmed.2008.04.001","article-title":"Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion","volume":"102","author":"Bale","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"7245","key":"10.1002\/14651858.CD002991.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/thorax.58.8.654","article-title":"Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study","volume":"58","author":"Burge","year":"2003","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/thorax.58.8.659","article-title":"Bronchodilator reversibility testing in chronic obstructive pulmonary disease","volume":"58","author":"Calverley","year":"2003","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1378\/chest.124.4.1350","article-title":"Withdrawal from treatment as an outcome in the ISOLDE study of COPD","volume":"124","author":"Calverley","year":"2003","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1378\/chest.125.6.2368","article-title":"Withdrawal of treatment in the ISOLDE study [letter]","volume":"125","author":"D'Urzo","year":"2004","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0954-6111(99)90001-X","article-title":"An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group","volume":"93","author":"Jarad","year":"1999","journal-title":"Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1183\/09031936.03.00013303","article-title":"Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations","volume":"21","author":"Jones","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1164\/ajrccm.163.1.2005009","article-title":"Health status deterioration in patients with chronic obstructive pulmonary disease","volume":"163","author":"Spencer","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1183\/09031936.04.00121404","article-title":"Impact of preventing exacerbations on deterioration of health status in COPD","volume":"23","author":"Spencer","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"9356","key":"10.1002\/14651858.CD002991.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0014|cit14","first-page":"242s [P1572]","article-title":"Safety of salmeterol\/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease","volume":"20","author":"Calverley","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0015|cit15","unstructured":"Calverley PM Pauwels RA Vestbo J Jones PW Pride NB Gulsvik A Clinical improvements with salmeterol \/ fluticasone propionate combination in differing severities of COPD [A035] [Poster D50] www.abstracts2view.com"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0016|cit16","unstructured":"Calverley PM Pauwels RA Vestbo J Jones PW Pride NB Gulsvik A Salmeterol\/fluticasone propionate combination for one year provides greater clinical benefit than its individual components www.abstracts-on-line.com\/abstracts\/ATS"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0017|cit17","unstructured":"A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of the salmeterol\/FP combination product at a strength of 50\/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS\u2122\/ACCUHALER\u2122, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months www.gsk-studyregister.com\/en\/trial-details\/?id=SFCB3024"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0018|cit18","unstructured":"Hunjan MK Chandler F Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol\/fluticasone propionate combination (SFC) and associated costs [Abstract] American Thoracic Society 100th international conference; 2004 May 21-26; Orlando 2004 D22 Poster 503"},{"issue":"Suppl 48","key":"10.1002\/14651858.CD002991.pub4-BIB0019|cit19","first-page":"291s","article-title":"Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol\/fluticasone propionate combination (Seretide) and salmeterol","volume":"24","author":"Hunjan","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"Suppl 48","key":"10.1002\/14651858.CD002991.pub4-BIB0020|cit20","first-page":"513s","article-title":"Salmeterol\/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate\/severe COPD","volume":"24","author":"Hunjan","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0021|cit21","unstructured":"Jones PW Edin HM Anderson J Salmeterol\/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference [A39] [Poster K39] www.abstracts-on-line.com\/abstracts\/ATS"},{"issue":"Suppl 49","key":"10.1002\/14651858.CD002991.pub4-BIB0022|cit22","first-page":"Abstract No. 13","article-title":"Budesonide\/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]","volume":"26","author":"Jones","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0023|cit23","unstructured":"Jones PW Vestbo J Pauwels RA Calverley PM Anderson JA Spencer MD Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna 2003 P1593"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0024|cit24","first-page":"727","article-title":"Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study","volume":"45","author":"Nitschmann","year":"2004","journal-title":"German Internist"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0025|cit25","first-page":"240 [P1569]","article-title":"Reduction of exacerbations with salmeterol\/fluticasone combination 50\/500 mcg bd in the treatment of chronic obstructive pulmonary disease","volume":"20","author":"Pauwels","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0026|cit26","unstructured":"Pauwels RA Vestbo J Calverley PM Jones PW Pride NB Gulsvik A Characterization of exacerbations in the TRISTAN study of salmeterol \/ fluticasone propionate (SFC) combination in moderate to severe COPD www.abstracts2view.com"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00019053-200523060-00008","article-title":"Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease","volume":"23","author":"Spencer","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 48","key":"10.1002\/14651858.CD002991.pub4-BIB0028|cit28","first-page":"290s","article-title":"The clinical significance of treatment benefits with the salmeterol\/fluticasone propionate 50\/500mcg combination in COPD","volume":"24","author":"Spencer","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0029|cit29","first-page":"240 [P1570]","article-title":"Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease","volume":"20","author":"Vestbo","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/thx.2004.025411","article-title":"Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease","volume":"60","author":"Vestbo","year":"2005","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0031|cit31","unstructured":"Vestbo J Pauwels RA Calverley PM Jones PW Pride NB Gulsvik A Salmeterol\/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD www.abstracts2view.com"},{"issue":"11","key":"10.1002\/14651858.CD002991.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.rmed.2004.03.017","article-title":"Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD","volume":"98","author":"Vestbo","year":"2004","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0033|cit33","unstructured":"Borgstrom L Asking L Olsson H Peterson S Lack of interaction between disease severity and therapeutic response with budesonide\/formoterol in a single inhaler [Abstract] American Thoracic Society 100th international conference; 2004 May 21-26; Orlando 2004"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002991.pub4-BIB0035|cit35","first-page":"P436","article-title":"Budesonide\/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002991.pub4-BIB0036|cit36","first-page":"P1587","article-title":"COPD exacerbations are reduced by budesonide\/formoterol in a single inhaler [Abstract]","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0037|cit37","unstructured":"Calverley PM Olsson H Symbicort International COPD Study Group Budesonide\/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract] American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle 2003 B024 Poster 418"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0038|cit38","unstructured":"Calverley PM Peterson S Combining budesonide\/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract] American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle 2003 D092 Poster 211"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0039|cit39","unstructured":"Calverley PM Stahl E Jones PW Budesonide\/formoterol improves the general health status of patients with COPD [Abstract] American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego 2005"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002991.pub4-BIB0040|cit40","first-page":"P435","article-title":"Budesonide\/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0041|cit41","unstructured":"Halpin D St\u00e5hl E Lundback B Anderson F Peterson S Treatment costs and number needed to treat (NNT) with budesonide\/formoterol to avoid one exacerbation of COPD [Abstract] American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando 2004"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0042|cit42","unstructured":"Halpin DMG Larsson T Calverley PM How many patients with COPD must be treated with budesonide\/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract] American Thoracic Society 2005 International Conference; May 20-25; San Diego 2005"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0043|cit43","unstructured":"Jones PW St\u00e5hl E Budesonide\/formoterol in a single inhaler improves health status in patients with COPD [Abstract] American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle 2003"},{"issue":"Suppl 49","key":"10.1002\/14651858.CD002991.pub4-BIB0044|cit44","first-page":"1352","article-title":"Budesonide\/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]","volume":"26","author":"Jones","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0045|cit45","unstructured":"Jones PW St\u00e5hl E Reducing exacerbations leads to a better health-related quality of life in patients with COPD European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna 2003"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002991.pub4-BIB0046|cit46","first-page":"P433","article-title":"Budesonide\/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]","volume":"22","author":"Lofdahl","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200523040-00006","article-title":"Cost effectiveness of budesonide\/formoterol in a single inhaler for COPD compared with each monocomponent used alone","volume":"23","author":"Lofdahl","year":"2005","journal-title":"Pharmacoeconomics"},{"issue":"88","key":"10.1002\/14651858.CD002991.pub4-BIB0048|cit48","first-page":"14","article-title":"Reducing the impact of COPD exacerbations: clinical efficacy of budesonide\/formoterol","volume":"13","author":"Lofdahl","year":"2004","journal-title":"European Respiratory Review"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD002991.pub4-BIB0049|cit49","first-page":"A149 [PS","article-title":"The TOwards a Revolution in COPD Health (TORCH) study: salmeterol\/fluticasone propionate improves survival in COPD over three years [Abstract]","volume":"11","author":"Calverley","year":"2006","journal-title":"Respirology"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/thx.2010.136077","article-title":"Cardiovascular events in patients with COPD: TORCH study results","volume":"65","author":"Calverley","year":"2010","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 50","key":"10.1002\/14651858.CD002991.pub4-BIB0052|cit52","first-page":"34s [E311]","article-title":"The TORCH (towards a revolution in COPD health) study salmeterol\/fluticasone propionate (SFC) improves survival in COPD over three years [Abstract]","volume":"28","author":"Calverley","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.1378\/chest.130.4_MeetingAbstracts.122S-a","article-title":"The towards a revolution in COPD health (TORCH) study: fluticasone propionate\/salmeterol improves survival in COPD over three years [Abstract]","volume":"130","author":"Calverley","year":"2006","journal-title":"Chest"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD002991.pub4-BIB0054|cit54","first-page":"A140 [O","article-title":"The TOwards a Revolution in COPD Health (TORCH) Study: salmeterol\/fluticasone propionate reduces the rate of exacerbations over three years [Abstract]","volume":"11","author":"Celli","year":"2006","journal-title":"Respirology"},{"issue":"Suppl 50","key":"10.1002\/14651858.CD002991.pub4-BIB0055|cit55","first-page":"34s [E312]","article-title":"The TORCH (towards a revolution in COPD health) study salmeterol\/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]","volume":"28","author":"Celli","year":"2006","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"177s","DOI":"10.1378\/chest.130.4_MeetingAbstracts.177S-a","article-title":"The towards a revolution in COPD health (TORCH) study: fluticasone propionate\/salmeterol reduces the rate of exacerbations over 3 years [Abstract]","volume":"130","author":"Celli","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0057|cit57","unstructured":"Celli B Ferguson GT Anderson JA Jenkins CR Jones PW Vestbo J Salmeterol\/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract] American Thoracic Society International Conference; 2007 May 18-23; San Francisco San Francisco, California, USA 2007 A763"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1164\/rccm.201004-0665OC","article-title":"Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience","volume":"183","author":"Celli","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"178s","DOI":"10.1378\/chest.130.4_MeetingAbstracts.178S-a","article-title":"The towards a revolution in COPD health (TORCH) study: fluticasone propionate\/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]","volume":"130","author":"Ferguson","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0061|cit61","unstructured":"Ferguson GT Calverley PM Anderson JA Celli B Jenkins CR Jones PW Effect of salmeterol\/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract] American Thoracic Society International Conference; 2007 May 18-23; San Francisco 2007 A763"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1378\/chest.08-3016","article-title":"Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study","volume":"136","author":"Ferguson","year":"2009","journal-title":"Chest"},{"issue":"Suppl 50","key":"10.1002\/14651858.CD002991.pub4-BIB0063|cit63","first-page":"34s","article-title":"The TORCH (TOwards a Revolution in COPD Health) study: salmeterol\/fluticasone propionate (SFC) improves survival in COPD over three years","volume":"28","author":"Ferguson","year":"2006","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0064|cit64","unstructured":"A multicentre, randomised, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of salmeterol\/fluticasone propionate (SERETIDE\u00ae\/VIANI\u00ae\/ADVAIR\u00ae) 50\/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS\u00ae\/ACCUHALER\u00ae inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment www.gsk-studyregister.com\/en\/trial-details\/?id=SCO30003#documents-section"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1465-9921-10-59","article-title":"Efficacy of salmeterol\/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study","volume":"10","author":"Jenkins","year":"2009","journal-title":"Respiratory Research"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0066|cit66","unstructured":"Mehta RS Kathman SJ Daley-Yates PT Cahn T Beerahee M Kunka RL Pharmacokinetics and pharmacodynamics in COPD patients following long-term twice-daily treatment with salmeterol\/fluticasone propionate (SFC) 50\/500mg and the individual components [Abstract] American Thoracic Society International Conference; 2007 May 18-23; San Francisco 2007 Poster #A41"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1183\/09031936.04.00120603","article-title":"The TORCH (TOwards a Revolution in COPD Health) survival study protocol","volume":"24","author":"The TORCH study group","year":"2004","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0068|cit68","unstructured":"Calverley P Pauwels R Nieminem M Stryszak P Staudinger H Lee T Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS European Respiratory Society 13th Annual Congress; 2003 Sep 28-29; Vienna 2003 P155"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-9-73","article-title":"One-year treatment with mometasone furoate in chronic obstructive pulmonary disease","volume":"9","author":"Calverley","year":"2008","journal-title":"Respiratory Research"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD002991.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"709s","DOI":"10.1378\/chest.126.4_MeetingAbstracts.709S-c","article-title":"Mometasone furoate dry powder inhaler (MF-DPI) improves FEV1, symptoms, quality of life and reduces exacerbations in patients with COPD","volume":"236","author":"Nelson","year":"2004","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0071|cit71","first-page":"A463","article-title":"Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 years prospective multicentre study","volume":"151","author":"Derenne","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/thx.54.1.7","article-title":"Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis","volume":"54","author":"Grunsven","year":"1999","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0073|cit73","unstructured":"A multicentre, randomised, placebo-controlled, double-blind comparison with 3 parallel groups to investigate the efficacy and safety of inhaled glucocorticoid fluticasone (500 \u03bcg bd via Diskus\u2122) vs. oral glucocorticoid therapy vs. placebo in subjects with chronic obstructive airway disease (COPD) under therapy with salmeterol (50 \u03bcg bd) GlaxoSmithKline Clinical Trial Register 2005"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0074|cit74","unstructured":"A randomized, double-blind, parallel-group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-studyregister.com\/en\/trial-details\/?id=FLTA3025"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0075|cit75","unstructured":"A multicentre, randomised, double-blind, parallel group, placebo-controlled study to compare the efficacy and safety of inhaled salmeterol\/fluticasone propionate combination product 25\/250 \u00b5g two puffs bd and fluticasone propionate 250\u00b5g two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks www.gsk-studyregister.com\/en\/trial-details\/?id=SCO30002"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0076|cit76","unstructured":"A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg\/fluticasone propionate 250mcg BID (SFC 50\/250) compared to placebo in COPD subjects www.gsk-studyregister.com\/en\/trial-details\/?id=SFCA3007"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 micro g)\/salmeterol (50 micro g) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD002991.pub4-BIB0078|cit78","first-page":"A279","article-title":"Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus","volume":"163","author":"Hanania","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002991.pub4-BIB0079|cit79","first-page":"P434","article-title":"Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg\/fluticasone propionate 250mcg combination [Abstract]","volume":"22","author":"Horstman","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0080|cit80","unstructured":"Mahler DA Darken P Brown CP Knobil K Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract] US COPD Coalition National COPD Conference 2003; Nov 14-15, Arlington 2003 1081"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002991.pub4-BIB0081|cit81","first-page":"P429","article-title":"Predicting lung function responses to salmeterol\/fluticasone propionate combination therapy in COPD [Abstract]","volume":"22","author":"Mahler","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"9","key":"10.1002\/14651858.CD002991.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/thorax.57.9.799","article-title":"Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue","volume":"57","author":"Gizycki","year":"2002","journal-title":"Thorax"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1164\/rccm.2105025","article-title":"The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease","volume":"165","author":"Hattotuwa","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002991.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.rmed.2005.03.034","article-title":"Effects of inhaled HFA beclomethasone on pulmonary function and symptoms in patients with chronic obstructive pulmonary disease","volume":"99","author":"John","year":"2005","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0085|cit85","unstructured":"John M Bosse S Schumacher A Oltmanns U Witt C Effects of inhaled beclomethasone HFA 134 (qvar\/ventoiair) on health related quality of life in patients with chronic obstructive pulmonary disease [Abstract] American Thoracic Society International Conference; 2005 May 20-25; San Diego 2005 Poster A43"},{"issue":"10","key":"10.1002\/14651858.CD002991.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1183\/09031936.93.06101479","article-title":"Quality-of-life in a long-term multicentre trial in chronic nonspecific lung disease: assessment at baseline. The Dutch CNSLD Study Group","volume":"6","author":"Kaptein","year":"1993","journal-title":"European Respiratory Journal"},{"issue":"20","key":"10.1002\/14651858.CD002991.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199211123272003","article-title":"A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease","volume":"327","author":"Kerstjens","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD002991.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/thx.48.7.722","article-title":"Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group","volume":"48","author":"Kerstjens","year":"1993","journal-title":"Thorax"},{"issue":"11","key":"10.1002\/14651858.CD002991.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/thx.49.11.1109","article-title":"Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group","volume":"49","author":"Kerstjens","year":"1994","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1183\/09031936.93.06060868","article-title":"Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group","volume":"6","author":"Kerstjens","year":"1993","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD002991.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/thx.49.7.652","article-title":"Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group","volume":"49","author":"Kerstjens","year":"1994","journal-title":"Thorax"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD002991.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1164\/ajrccm.151.2.7842192","article-title":"Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group","volume":"151","author":"Kerstjens","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1378\/chest.110.1.35","article-title":"Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups","volume":"110","author":"Overbeek","year":"1996","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0094|cit94","first-page":"975","article-title":"Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease","volume":"151","author":"Rutten-van Molken","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/thx.54.1.7","article-title":"Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis","volume":"54","author":"Grunsven","year":"1999","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.rmed.2012.12.014","article-title":"A randomised trial of fluticasone furoate\/vilanterol (50\/25 mug; 100\/25 mug) on lung function in COPD","volume":"107","author":"Kerwin","year":"2013","journal-title":"Respiratory Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-151-8-200910200-00004","article-title":"Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial","volume":"151","author":"Lapperre","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0098|cit98","first-page":"244s","article-title":"Inhaled budesonide in the management of chronic obstructive pulmonary disease","volume":"20","author":"Laptseva","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1164\/rccm.2112096","article-title":"Smoking and lung function of Lung Health Study participants after 11 years","volume":"166","author":"Anthonisen","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1378\/chest.124.1.57","article-title":"Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II","volume":"124","author":"Eichenhorn","year":"2003","journal-title":"Chest"},{"issue":"26","key":"10.1002\/14651858.CD002991.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","article-title":"Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease","volume":"343","author":"Lung Health Study Research Group","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1164\/rccm.200310-1349OC","article-title":"Loss of one density with inhaled triamcinolone in Lung Health Study II","volume":"170","author":"Scanlon","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0012-3692(15)31287-3","article-title":"Skin manifestations of inhaled corticosteroids in COPD patients","volume":"126","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0104|cit104","unstructured":"A randomized, double-blind, placebo-controlled, parallel-group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg\/fluticasone propionate 500mcg BID (SFC 50\/500) compared to placebo in COPD subjects www.gsk-studyregister.com\/en\/trial-details\/?id=SFCA3006"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0105|cit105","unstructured":"Mahler DA Darken P Brown CP Knobil K Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) www.abstracts2view.com"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.rmed.2012.12.016","article-title":"Fluticasone furoate\/vilanterol (100\/25; 200\/25 mug) improves lung function in COPD: a randomised trial","volume":"107","author":"Martinez","year":"2013","journal-title":"Respiratory Medicine"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2165\/00044011-200121120-00006","article-title":"Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease","volume":"21","author":"Mirici","year":"2001","journal-title":"Clinical Drug Investigation"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.rmed.2005.04.025","article-title":"The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients","volume":"99","author":"Ozol","year":"2005","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0110|cit110","unstructured":"A multi-centre, randomised, double-blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000\u00b5g daily with placebo in chronic obstructive pulmonary disease ctr.gsk.co.uk 2005"},{"issue":"9105","key":"10.1002\/14651858.CD002991.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(97)03471-5","article-title":"Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group","volume":"351","author":"Paggiaro","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1183\/09031936.02.00276602","article-title":"Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler","volume":"19","author":"Johnell","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0954-6111(98)90293-1","article-title":"The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies","volume":"92","author":"Lofdahl","year":"1998","journal-title":"Respiratory Medicine"},{"issue":"25","key":"10.1002\/14651858.CD002991.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","article-title":"Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease","volume":"340","author":"Pauwels","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD002991.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1183\/09031936.93.05101254","article-title":"European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design","volume":"5","author":"Pauwels","year":"1992","journal-title":"European Respiratory Journal"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1378\/chest.109.5.1156","article-title":"Effects of long-term treatment with corticosteroids in COPD","volume":"109","author":"Renkema","year":"1996","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/thx.54.1.7","article-title":"Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis","volume":"54","author":"Grunsven","year":"1999","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/COPD.S8196","article-title":"Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study","volume":"4","author":"Chavannes","year":"2009","journal-title":"International Journal of COPD"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.rmed.2008.11.003","article-title":"Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis","volume":"103","author":"Schermer","year":"2009","journal-title":"Respiratory Medicine"},{"issue":"10","key":"10.1002\/14651858.CD002991.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0954-6111(99)90038-0","article-title":"Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease","volume":"93","author":"Senderovitz","year":"1999","journal-title":"Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/15412550902772593","article-title":"The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography","volume":"6","author":"Shaker","year":"2009","journal-title":"COPD"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15412555.2010.541306","article-title":"Rapid fall in lung density following smoking cessation in COPD","volume":"8","author":"Shaker","year":"2011","journal-title":"COPD"},{"issue":"Suppl III","key":"10.1002\/14651858.CD002991.pub4-BIB0123|cit123","first-page":"iii43","article-title":"Budesonide\/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD","volume":"57","author":"Anderson","year":"2002","journal-title":"Thorax"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002991.pub4-BIB0124|cit124","first-page":"P435","article-title":"Budesonide\/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002991.pub4-BIB0125|cit125","first-page":"S145","article-title":"Effect of budesonide\/formoterol on severe exacerbations and lung function in moderate to severe COPD","volume":"57\u00a0","author":"Calverley","year":"2002","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0126|cit126","unstructured":"Campbell LM Szafranski W Budesonide\/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD BTS Winter Meeting, 2002 Dec 4-6; London 2002 S143"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0127|cit127","unstructured":"Campbell LW Szafranski W Budesonide\/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate-severe COPD BTS Winter Meeting, 2002 Dec 4-6; London 2002 S141"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0128|cit128","first-page":"242 [P1575]","article-title":"Budesonide\/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD","volume":"20","author":"Dahl","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0129|cit129","first-page":"242 [P1574]","article-title":"Budesonide\/formoterol in a single inhaler provides sustained relief from symptoms and night-time awakenings in moderate-severe COPD: results from symptoms and night-time awakenings in moderate to severe COPD: results from a 1-year study","volume":"20","author":"Egede","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0130|cit130","unstructured":"Halpin D Stahl E Lundback B Anderson F Peterson S Treatment costs and number needed to treat (NNT) with budesonide\/formoterol to avoid one exacerbation of COPD [Abstract] American Thoracic Society 100th international conference; 2004 May 21-26; Orlando 2004 D22 Poster 525"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0131|cit131","first-page":"250 [P1613]","article-title":"Improvement in health status in patients with moderate to severe COPD after treatment with budesonide\/formoterol in a single inhaler","volume":"20","author":"Jones","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0132|cit132","first-page":"242 [P1577]","article-title":"Budesonide\/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1-year study of patients with moderate to severe COPD","volume":"20","author":"Korsgaard","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0133|cit133","first-page":"242 [P1573]","article-title":"Budesonide\/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study","volume":"20","author":"Lange","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"88","key":"10.1002\/14651858.CD002991.pub4-BIB0134|cit134","first-page":"14","article-title":"Reducing the impact of COPD exacerbations: clinical efficacy of budesonide\/formoterol","volume":"13","author":"Lofdahl","year":"2004","journal-title":"European Respiratory Review"},{"issue":"Suppl 38","key":"10.1002\/14651858.CD002991.pub4-BIB0135|cit135","first-page":"242 [P1576]","article-title":"Budesonide\/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD","volume":"20","author":"Milanowski","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0137|cit137","unstructured":"Szfranski W Ramirez A Peterson S Budesonide\/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract] European Respiratory Society 12th Annual Congress; 2002 Sep 14-18; Stockholm 2002"},{"issue":"14","key":"10.1002\/14651858.CD002991.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","article-title":"Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial","volume":"68","author":"Tashkin","year":"2008","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0139|cit139","first-page":"73","article-title":"Efficacy and safety characteristics of mometasone furoate\/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials","volume":"7","author":"Tashkin","year":"2012","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"9167","key":"10.1002\/14651858.CD002991.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(98)10019-3","article-title":"Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial","volume":"353","author":"Vestbo","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2222.1999.00021.x","article-title":"A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease","volume":"29","author":"Weir","year":"1999","journal-title":"Clinical and Experimental Allergy Supplement"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1440-1843.2004.00618.x","article-title":"Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?","volume":"9","author":"Yildiz","year":"2004","journal-title":"Respirology"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1378\/chest.126.6.1815","article-title":"Efficacy of inhaled steroids in undiagnosed subjects at high risk for COPD: results of the detection, intervention, and monitoring of COPD and asthma program","volume":"126","author":"Albers","year":"2004","journal-title":"Chest"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0145|cit145","first-page":"9","article-title":"Inhaled glucocorticoids do not help smokers with mild chronic obstructive pulmonary disease","volume":"42","year":"1999","journal-title":"Modern Medicine of Australia"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0146|cit146","first-page":"21","article-title":"Inhaled corticosteroids: their role in chronic obstructive pulmonary disease","volume":"11","year":"2000","journal-title":"MeReC Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/thx.46.5.372","article-title":"Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease","volume":"46","author":"Auffarth","year":"1991","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1378\/chest.117.6.1633","article-title":"Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation?","volume":"117","author":"Balbi","year":"2000","journal-title":"Chest"},{"issue":"Suppl 45","key":"10.1002\/14651858.CD002991.pub4-BIB0149|cit149","first-page":"282s","article-title":"Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma","volume":"22","author":"Bensch","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"1053","key":"10.1002\/14651858.CD002991.pub4-BIB0150|cit150","first-page":"370","article-title":"The efficacy of inhaled corticosteroids in the management of non asthmatic chronic airflow obstruction","volume":"110","author":"Boothman-Burrell","year":"1997","journal-title":"New Zealand Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/thx.2004.032516","article-title":"Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease","volume":"60","author":"Brightling","year":"2005","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD002991.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/thx.54.7.655a","article-title":"Inhaled corticosteroids in COPD","volume":"54","author":"Burge","year":"1999","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0153|cit153","first-page":"97","article-title":"The effects of inhaled corticosteroids on chronic airflow limitation","volume":"11","author":"Chan","year":"1993","journal-title":"Asian Pacific Journal of Allergy and Immunology"},{"issue":"7","key":"10.1002\/14651858.CD002991.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/thx.53.7.583","article-title":"Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease","volume":"53","author":"Confalonieri","year":"1998","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000119718","article-title":"Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD","volume":"76","author":"Corda","year":"2008","journal-title":"Respiration"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1378\/chest.115.5.1271","article-title":"A randomised controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers","volume":"115","author":"Cox","year":"1999","journal-title":"Chest"},{"issue":"5 Pt 1","key":"10.1002\/14651858.CD002991.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1164\/ajrccm.160.5.9811058","article-title":"Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease","volume":"160","author":"Culpitt","year":"1999","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1183\/09031936.93.05080945","article-title":"Inhaled beclomethasone improves the course of asthma and COPD","volume":"5","author":"Dompeling","year":"1992","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD002991.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"770","DOI":"10.7326\/0003-4819-118-10-199305150-00003","article-title":"Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids","volume":"118","author":"Dompeling","year":"1993","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0160|cit160","first-page":"1267","article-title":"A randomised, double blind study comparing the effects of beclomethasone and fluticasone on bone density over 2 years","volume":"13","author":"Egan","year":"1999","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD002991.pub4-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1183\/09031936.93.02100935","article-title":"A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis","volume":"2","author":"Engel","year":"1989","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF03320543","article-title":"Cost-analysis of four treatment strategies in the management of moderate-to-severe COPD: an application non-parametric bootstrap","volume":"72","author":"Fattore","year":"2005","journal-title":"Pharmacoeconomics Italian Research Articles"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000194908","article-title":"Beclomethasone dipropionate does not affect mucociliary clearance in patients with chronic obstructive lung disease","volume":"50","author":"Fazio","year":"1986","journal-title":"Respiration"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1164\/ajrccm.164.6.2012139","article-title":"Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effects of inhaled beclomethasone","volume":"164","author":"Ferreira","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0165|cit165","unstructured":"Ferreira IM Sandrini A Zamel N Balter M Chapman KR Effects of inhaled fluticasone propionate (FP) on Exhaled Nitric Oxide (ENO), functional exercise capacity and quality of life in stable patients with COPD American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle 2003 B024 Poster 404"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.rmed.2011.08.021","article-title":"Effect of adjunct fluticasone propionate on airway physiology during rest and exercise in COPD","volume":"105","author":"Guenette","year":"2011","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0167|cit167","first-page":"241","article-title":"Effect of single inhalation of a salbutamol, ipratropium bromide and beclomethasone on mucociliary clearance in patients with chronic obstructive airway disease","volume":"45","author":"Guleria","year":"2003","journal-title":"Indian Journal of Chest Diseases and Allied Sciences"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1164\/ajrccm.155.2.9032192","article-title":"Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD","volume":"155","author":"Keatings","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD002991.pub4-BIB0169|cit169","first-page":"542","article-title":"Inhalative Budesonid-Therapie bei chronischer Bronchitis","volume":"23","author":"Kozak-Skzopek","year":"1997","journal-title":"Atemweg und Lungenerkrankheiten"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1164\/ajrccm.153.2.8564107","article-title":"Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema","volume":"153","author":"Llewellyn-Jones","year":"1996","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/rmed.2000.0960","article-title":"In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation","volume":"95","author":"Loppow","year":"2001","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0172|cit172","first-page":"184","article-title":"The efficacy of steroid aerosol in chronic obstructive pulmonary disease (COPD)","volume":"113","author":"Matlin","year":"1976","journal-title":"American Review of Respiratory Disease"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0173|cit173","first-page":"224","article-title":"Four-week nebulized beclomethasone dipropionate in stable COPD patients with exertional dyspnoea","volume":"54","author":"Melani","year":"1999","journal-title":"Monaldi Archives for Chest Disease"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0174|cit174","first-page":"160","article-title":"AeroBec Autohaler in patients with reversible chronic-obstructive respiratory diseases","volume":"25","author":"Moller","year":"1999","journal-title":"Atemwegs- Und Lungenkrankheiten"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1378\/chest.118.4.990","article-title":"Controlled short-term trial of fluticasone propionate in ventilator-dependent patients with COPD","volume":"118","author":"Nava","year":"2000","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0176|cit176","unstructured":"Chronic Obstructive Pulmonary Disease Endpoints Study www.clinicaltrials.gov\/ct2\/show\/NCT00358358"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1378\/chest.115.1.31","article-title":"The effect of high-dose inhaled beclomethasone dipropionate in patients with stable COPD","volume":"115","author":"Nishimura","year":"1999","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/pupt.2000.0249","article-title":"Additive effects of prednisolone and beclomethasone dipropionate in patients with stable chronic obstructive pulmonary disease","volume":"13","author":"Nishimura","year":"2000","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1164\/ajrccm.164.3.2002052","article-title":"Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction","volume":"164","author":"O'Brien","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0180|cit180","first-page":"497","article-title":"Clinical study of inhaled corticosteroid in non-asthmatic chronic obstructive pulmonary disease","volume":"21","author":"Ouyang","year":"1998","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1440-1843.2008.01380.x","article-title":"Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related","volume":"13","author":"Reid","year":"2008","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0182|cit182","first-page":"565","article-title":"A double-blind comparison of oral prednisolone 40 mg\/day with inhaled beclomethasone dipropionate 1500 ug\/day in patients with adult onset chronic obstructive airways disease","volume":"146","author":"Robertson","year":"1986","journal-title":"European Journal of Respiratory Diseases"},{"issue":"24","key":"10.1002\/14651858.CD002991.pub4-BIB0183|cit183","first-page":"1380","article-title":"Inhaled corticosteroids are effective and well tolerated","volume":"46","author":"Roth","year":"1996","journal-title":"Therapiewoche"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD002991.pub4-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1164\/ajrccm.157.3.9709100","article-title":"Short-term treatment with budesonide does not improve hyperresponsiveness to adenosine 5'-monophosphate in COPD","volume":"157","author":"Rutgers","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002991.pub4-BIB0185|cit185","first-page":"iii86","article-title":"Effect of inhaled steroid withdrawal on exhaled nitric oxide in COPD: preliminary data [Abstract]","volume":"58","author":"Sandrini","year":"2003","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2710.2000.00286.x","article-title":"Inhaled corticosteroids and chronic obstructive pulmonary disease","volume":"25","author":"Sapey","year":"2000","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1378\/chest.11-2535","article-title":"Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol","volume":"142","author":"Scherr","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0188|cit188","first-page":"28","article-title":"COPD \u2013 Therapie: Bronchodilatatoren und Steroide","volume":"17","author":"Schuurmans","year":"2001","journal-title":"Therapiewoche"},{"issue":"7","key":"10.1002\/14651858.CD002991.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1164\/rccm.200404-543OC","article-title":"Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease","volume":"170","author":"Sin","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002991.pub4-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1164\/rccm.200709-1356OC","article-title":"The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease","volume":"177","author":"Sin","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0191|cit191","unstructured":"Spicuzza L Scuderi V Prosperini G Balsamo R DiMara GU Polosa R Acute effect of inhaled fluticasone on airway hyperresponsiveness to adenosine 5'-monophosphate in asthma and in COPD American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando 2004"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1164\/ajrccm\/146.2.389","article-title":"Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation","volume":"146","author":"Thompson","year":"1992","journal-title":"American Review of Respiratory Disease"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s004080000093","article-title":"Controlled trial of inhaled fluticasone propionate in moderate to severe COPD","volume":"180","author":"Thompson","year":"2002","journal-title":"Lung"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/thx.54.2.186","article-title":"Inhaled corticosteroids in COPD","volume":"54","author":"Tsang","year":"1999","journal-title":"Thorax"},{"issue":"Suppl 48","key":"10.1002\/14651858.CD002991.pub4-BIB0195|cit195","first-page":"289s","article-title":"High dose inhaler corticosteroids in patients with COPD","volume":"24","author":"Turker","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD002991.pub4-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1164\/ajrccm.164.11.2003151","article-title":"The cost effectiveness of early treatment with fluticasone propionate 250 mcg twice a day in subjects with obstructive airway disease: results of the DIMCA program","volume":"164","author":"den Boom","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"10","key":"10.1002\/14651858.CD002991.pub4-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.200206-512OC","article-title":"Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study","volume":"166","author":"Valk","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02770900009055445","article-title":"Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study","volume":"37","author":"Grunsven","year":"2000","journal-title":"Journal of Asthma"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.rmed.2003.08.001","article-title":"Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study","volume":"97","author":"Grunsven","year":"2003","journal-title":"Respiratory Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1378\/chest.107.5.1199","article-title":"The influence of an inhaled steroid on quality of life in patients with asthma or COPD","volume":"107","author":"Schayck","year":"1995","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/09629350123056","article-title":"Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease","volume":"10","author":"Verhoeven","year":"2001","journal-title":"Mediators of Inflammation"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/thorax.57.8.694","article-title":"Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness","volume":"57","author":"Verhoeven","year":"2002","journal-title":"Thorax"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/096293500411578","article-title":"Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients","volume":"9","author":"Verhoeven","year":"2000","journal-title":"Mediators of Inflammation"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0204|cit204","first-page":"493","article-title":"Long-term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The \u00d8sterbro Study","volume":"162","author":"Vestbo","year":"2000","journal-title":"Ugeskrift for L\u00e6ger"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1378\/chest.101.2.350","article-title":"Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator responsiveness in middle-aged smokers with mild airflow obstruction","volume":"101","author":"Watson","year":"1992","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1378\/chest.108.6.1568","article-title":"Inhaled budesonide therapy for patients with stable COPD","volume":"108","author":"Weiner","year":"1995","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD002991.pub4-BIB0207|cit207","first-page":"823","article-title":"Inhaled budesonide for chronic obstructive pulmonary disease","volume":"132","author":"Weiner","year":"1997","journal-title":"Harefuah"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2796.1999.00412.x","article-title":"The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease","volume":"245","author":"Weiner","year":"1999","journal-title":"Journal of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/thx.45.2.112","article-title":"Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate","volume":"45","author":"Weir","year":"1990","journal-title":"Thorax"},{"issue":"10","key":"10.1002\/14651858.CD002991.pub4-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.93.04101185","article-title":"Response to corticosteroids in chronic airflow obstruction: relationship to emphysema and airways collapse","volume":"4","author":"Weir","year":"1991","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thx.45.2.118","article-title":"Time course of response to oral and inhaled corticosteroids in non-asthmatic chronic airflow obstruction","volume":"45","author":"Weir","year":"1990","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/thx.48.4.309","article-title":"Effects of high dose inhaled beclomethasone dipropionate, 750 mcg and 1500 mcg twice daily, and 40 mg per day oral prednisolone on lung function, symptoms, and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction","volume":"48","author":"Weir","year":"1993","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/thx.47.8.616","article-title":"Effects of corticosteroids on bronchodilator action in chronic obstructive lung disease","volume":"47","author":"Wempe","year":"1992","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD002991.pub4-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1183\/09031936.93.04091101","article-title":"Inhaled budesonide in chronic bronchitis. Effects on respiratory impedance","volume":"4","author":"Wesseling","year":"1991","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD002991.pub4-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00063198-200003000-00004","article-title":"Inhaled steroid therapy in chronic obstructive pulmonary disease","volume":"6","author":"Whittaker","year":"2000","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0954-6111(97)90030-5","article-title":"The effect of inhaled glucocorticosteroids in emphysema due to alpha1-antitrypsin deficiency","volume":"91","author":"Wilcke","year":"1997","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0217|cit217","unstructured":"Williamson P Menzies D Clearie K Vaidyanathan S Lipworth B Dose response for inhaled fluticasone on airway and systemic inflammation in COPD [Abstract] European Respiratory Society 19th Annual Congress; 2009 Sep 12-15; Vienna 2009"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000029466","article-title":"Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease","volume":"67","author":"Yildiz","year":"2000","journal-title":"Respiration"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMra1900475","article-title":"Update on the pathogenesis of chronic obstructive pulmonary disease","volume":"381","author":"Agust\u00ed","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/thorax.58.8.654","article-title":"Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study","volume":"58","author":"Burge","year":"2003","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1378\/chest.124.4.1350","article-title":"Withdrawal from treatment as an outcome in the ISOLDE study of COPD","volume":"124","author":"Calverley","year":"2003","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMra1900500","article-title":"Update on clinical aspects of chronic obstructive pulmonary disease","volume":"381","author":"Celli","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5694\/mja2.51708","article-title":"COPD-X Australian guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2022 update","volume":"217","author":"Dabscheck","year":"2022","journal-title":"Medical Journal of Australia"},{"issue":"20","key":"10.1002\/14651858.CD002991.pub4-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2008.717","article-title":"Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"300","author":"Drummond","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1378\/chest.124.1.57","article-title":"Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II","volume":"124","author":"Eichenhorn","year":"2003","journal-title":"Chest"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD002991.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"S2117","DOI":"10.21037\/jtd.2019.10.53","article-title":"Diagnostic approach to chronic dyspnoea in adults","volume":"11","author":"Ferry","year":"2019","journal-title":"Journal of Thoracic Disease"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1370\/afm.517","article-title":"Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes","volume":"4","author":"Gartlehner","year":"2006","journal-title":"Annals of Family Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0229|cit229","unstructured":"Global Initiative for Chronic Obstructive Pulmonary Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2023 report goldcopd.org\/2023-gold-report-2\/"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0230|cit230","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0231|cit231","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-138-12-200306170-00008","article-title":"Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysis","volume":"138","author":"Highland","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002991.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1183\/09031936.02.00276602","article-title":"Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler","volume":"19","author":"Johnell","year":"2002","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0234|cit234","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010115.pub2","article-title":"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease","author":"Kew","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD002991.pub4-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/resp.12780","article-title":"Acute exacerbation of chronic obstructive pulmonary disease","volume":"21","author":"Ko","year":"2016","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0236|cit236","doi-asserted-by":"publisher","first-page":"210075","DOI":"10.1183\/16000617.0075-2021","article-title":"Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD","volume":"30","author":"Miravitlles","year":"2021","journal-title":"European Respiratory Review"},{"issue":"8","key":"10.1002\/14651858.CD002991.pub4-BIB0237|cit237","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006826.pub2","article-title":"Combined corticosteroid and long-acting beta2-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease","author":"Nannini","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0238|cit238","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1164\/rccm.200310-1349OC","article-title":"Loss of bone density with inhaled triamcinolone in Lung Health Study II","volume":"170","author":"Scanlon","year":"2004","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"12","key":"10.1002\/14651858.CD002991.pub4-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/thx.2005.045385","article-title":"Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease","volume":"60","author":"Sin","year":"2005","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/archinternmed.2008.550","article-title":"Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis","volume":"169","author":"Singh","year":"2009","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1378\/chest.06-1696","article-title":"A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo","volume":"131","author":"Soriano","year":"2007","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD002991.pub4-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/thorax.58.11.937","article-title":"Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis","volume":"58","author":"Sutherland","year":"2003","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/thx.54.1.7","article-title":"Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis","volume":"54","author":"Grunsven","year":"1999","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0245|cit245","doi-asserted-by":"crossref","unstructured":"Welte T Inhaled corticosteroids in COPD and the risk of pneumonia Lancet 2009 374 9691 668 70","DOI":"10.1016\/S0140-6736(09)61540-3"},{"issue":"3","key":"10.1002\/14651858.CD002991.pub4-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1586\/17476348.2016.1151789","article-title":"Use of inhaled corticosteroids in COPD: improving efficacy","volume":"10","author":"Yang","year":"2016","journal-title":"Expert Review of Respiratory Medicine"},{"key":"10.1002\/14651858.CD002991.pub4-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"105950","DOI":"10.1016\/j.intimp.2019.105950","article-title":"Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials","volume":"77","author":"Yang","year":"2019","journal-title":"International Immunopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD002991.pub4-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(21)00506-3","article-title":"COPD in never smokers: pathogenesis and implications for prevention and treatment","volume":"10","author":"Yang","year":"2022","journal-title":"Lancet Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002991.pub4-BIB0249|cit249","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002991","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002991.pub4-BIB0250|cit250","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002991.pub2","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD002991.pub4-BIB0251|cit251","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002991.pub3","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","author":"Yang","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T10:03:53Z","timestamp":1754561033000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002991.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":251,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002991.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}